View in EDS

ROAR trial: which treatment is effective after progression? - Authors' reply.

Saved in:
Bibliographic Details
Title: ROAR trial: which treatment is effective after progression? - Authors' reply.
Authors: Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: patrick_wen@dfci.harvard.edu., Burgess P; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals, Basel, Switzerland., Ilankumaran P; Global Drug Development, Oncology Development Unit, Novartis Pharma, East Hanover, NJ, USA., Subbiah V; Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: The Lancet. Oncology [Lancet Oncol] 2022 Mar; Vol. 23 (3), pp. e94.
Publication Type: Letter; Comment
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35240095
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: ROAR trial: which treatment is effective after progression? - Authors' reply.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wen+PY%22">Wen PY</searchLink>; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: patrick_wen@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Burgess+P%22">Burgess P</searchLink>; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ilankumaran+P%22">Ilankumaran P</searchLink>; Global Drug Development, Oncology Development Unit, Novartis Pharma, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Subbiah+V%22">Subbiah V</searchLink>; Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2022 Mar; Vol. 23 (3), pp. e94.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter; Comment
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35240095
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(22)00076-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e94
    Titles:
      – TitleFull: ROAR trial: which treatment is effective after progression? - Authors' reply.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wen PY
      – PersonEntity:
          Name:
            NameFull: Burgess P
      – PersonEntity:
          Name:
            NameFull: Ilankumaran P
      – PersonEntity:
          Name:
            NameFull: Subbiah V
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2022 Mar
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1